Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006

Diagnostic Microbiology and Infectious Disease

Volumn 62, Issue 1, 2008, Pages 67-80

  Zhanel, George G ^a,b   DeCorby, Mel ^a,b   Nichol, Kim A ^a,b   Wierzbowski, Aleksandra ^a,b   Baudry, Patricia J ^a,b   Karlowsky, James A ^a,b   Lagacé Wiens, Philippe ^a,b   Walkty, Andrew ^a,b   Mulvey, Michael R ^c   Hoban, Daryl J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Intensive care units; Resistance; Susceptibility

Indexed keywords

AMIKACIN; BETA LACTAMASE; CEFEPIME; DALBAVANCIN; DAPTOMYCIN; LINEZOLID; MEROPENEM; METICILLIN; PIPERACILLIN; QUINOLONE DERIVATIVE; SULFAMETHOXAZOLE; TAZOBACTAM; TIGECYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CANADA; CONTROLLED STUDY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; CANADA; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE;

EID: 49549091553     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.04.012     Document Type: Article

References (25)

1. Anonymous. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Cont. 31 (2003) 481-498
2. Chambers H.F. Community-associated MRSA-resistance and virulence converge. N. Engl. J. Med. 352 (2005) 1485-1487
3. Chen D.K., McGeer A., de Azavedo J.C., and Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341 (1999) 233-239
4. Christianson S., Golding G.R., Campbell J., and Mulvey M.R. Comparative genomics of Canadian epidemic lineages of methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 45 (2007) 1904-1911
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 16th informational supplement document M100-S16. CLSI/NCCLS M100-S15 (2006), Clinical and Laboratory Standards Institute, Wayne, PA
6. Deshpande L.M., Fritsche T.R., Moet G.J., Biedenbach D.J., and Jones R.N. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 58 (2007) 163-170
7. Hoban D.J., Bouchillon S.K., and Dowzicky M.J. Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multi-drug resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline a new glycylcycline antimicrobial. Diagn. Microbiol. Infect. Dis. 57 (2007) 423-428
8. Jones R.N., Fritsche T.R., Sader H.S., and Ross J.E. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn. Microbiol. Infect. Dis. 59 (2007) 309-317
9. Lockhart S.R., Abramson M.A., Beekman S.E., Gallagher G., Riedel S.R., Diekma D.J., Quinn J.P., and Doern G.V. Antimicrobial resistance among gram-negative bacilli as causes of infections in intensive care unit patients in the United States between 1993-2004. J. Clin. Microbiol. 45 (2007) 3352-3359
10. Mulvey M.R., Chiu L., Ismail J., Louie L., Murphy C., Chang N., and Alfa M. Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis. J. Clin. Microbiol. 39 (2001) 3481-3485
11. Mulvey M.R., Bryce E., Boyd D., Ofner-Agostini M., Christianson S., Simor A.E., and Paton S. Ampler class A extended-spectrum β-lactamase producing Escherichia coli and Klebsiella spp. in Canadian Hospitals. Antimicrob. Agents Chemother. 48 (2004) 1204-1214
12. Mulvey M.R., MacDougall L., Cholin B., Horsman G., Fidyk M., Woods S., and and the Saskatchewan CA-MRSA Study Group. Community-associated methicillin-resistant Staphylococcus aureus, Canada. Emerg. Infect. Dis. 11 (2005) 844-850
13. Oliveira D.C., and de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46 (2002) 2155-2161
14. Pfaller M.A., Sader H.S., and Jones R.N. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of gram-positive cocci collected in North American hospitals (2002-2005). Diagn. Microbiol. Infect. Dis. 57 (2007) 459-465
15. Pitout J.D.D., Church D.L., Gregson D.B., Chow B.L., McCracken M., Mulvey M., and Laupland K.B. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary health region: emergence of CTX-M-15-producing isolates. Antimicrob. Agents Chemother. 51 (2007) 1281-1286
16. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward gram-negative isolates from meropenem yearly susceptibility test information collection program (USA). Diagn. Microbiol. Infect. Dis. 56 (2006) 57-62
17. Rubinstein E., and Zhanel G.G. Anti-infective research and development problems challenges and solutions: the clinical practitioner perspective. Lancet Infect. Dis. 7 (2007) 69-70
18. Tenover F.C., Arbeit R.D., Goering R.V., Mickelson P.A., Murray B.E., and Persing B.H. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33 (1995) 2233-2239
19. Waites K.B., Duffy L.B., and Dowzicky M.J. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline a new glycylcycline antimicrobial. Antimicrob. Agents Chemother. 50 (2006) 3479-3484
20. Whitney C.G., Farley M.M., and Hadler J. Increasing prevalence of multi-drug resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343 (2000) 1817-1824
21. Ylipalosaari P., Ala-Kokko T.I., Laurila J., Ohtonene P., and Syrjala H. Epidemiology of intensive care unit (ICU)-acquired infections in a 14 month prospective cohort study in a single mixed Scandinavian university hospital ICU. Acta. Anaesthesiol. Scand. 50 (2006) 1192-1197
22. Zhanel G.G., Laing N.M., Nichol K.A., Palatnick L.P., Noreddin A., Hisanaga T., Johnson J.L., Hoban D.J., and the NAVRESS group. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North America Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J. Antimicrob. Chemother. 52 (2004) 382-388
23. Zhanel G.G., DeCorby M., Laing N., Weshnoweski B., Vashisht R., Tailor F., Nichol K.A., Wierzbowski A., Baudry P.J., Karlowsky J.A., Lagace-Wiens P., Walkty A., McCracken M., Mulvey M.R., Johnson J., Hoban D.J., and the Canadian Antimicrobial Resistance Alliance (CARA). Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005/2006. Antimicrob. Agents Chemother. 52 (2008) 1430-1437
24. Zhanel G.G., Trapp S., Gin A.S., DeCorby M., Lagace-Wiens P., Rubinstein E., Hoban D.J., and Karlowsky J.A. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of gram-positive infections. Expert. Rev. Anti. Infect. Ther. 6 (2008) 67-81
25. Zhanel G.G., DeCorby M., Nichol K.A., Baudry P., Karlowsky J.A., McCracken M., Mulvey M.R., Hoban D.J., and the Canadian Antimicrobial Resistance Alliance (CARA). Characterization of MRSA, VRE and ESBL producing E. coli in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005/2006. Can. J. Infect. Dis. Med. Microbiol. 19 (2008) 243-249